Trial Profile

A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADG 106 (Primary)
Indications Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Adagene

Most Recent Events

15 Oct 2022 Status changed from active, no longer recruiting to completed.
22 Jul 2022 Planned End Date changed from 30 Jun 2022 to 31 Aug 2022.
11 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com